COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
F. Martinez (New York, NY, United States of America), K. Rabe (Grosshansdorf, Germany), G. Ferguson (Farmington Hills, MI, United States of America), C. Wang (Beijing, China), D. Singh (Manchester, United Kingdom), J. Wedzicha (London, United Kingdom), R. Trivedi (Durham, NC, United States of America), E. St Rose (Morristown, NJ, United States of America), S. Ballal (Morristown, NJ, United States of America), J. Mclaren (Gaithersburg, MD, United States of America), P. Darken (Morristown, NJ, United States of America), M. Aurivillius (Gothenburg, Sweden), C. Reisner (Morristown, NJ, United States of America), P. Dorinsky (Durham, NC, United States of America)
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Martinez (New York, NY, United States of America), K. Rabe (Grosshansdorf, Germany), G. Ferguson (Farmington Hills, MI, United States of America), C. Wang (Beijing, China), D. Singh (Manchester, United Kingdom), J. Wedzicha (London, United Kingdom), R. Trivedi (Durham, NC, United States of America), E. St Rose (Morristown, NJ, United States of America), S. Ballal (Morristown, NJ, United States of America), J. Mclaren (Gaithersburg, MD, United States of America), P. Darken (Morristown, NJ, United States of America), M. Aurivillius (Gothenburg, Sweden), C. Reisner (Morristown, NJ, United States of America), P. Dorinsky (Durham, NC, United States of America). COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels. 977
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Asthma control with a breath-actuated pressurised metered dose inhaler (BAI) and prevalence of oral candidiasis: a prescribing claims study of 1701 patients prescribed a traditional pressurised metered dose inhaler (MDI) plus spacer or a BAI Source: Eur Respir J 2002; 20: Suppl. 38, 78s Year: 2002
Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Sub-microgram dose formulations for dose ranging studies with long acting bronchodilators and their fixed dose combination using metered dose inhalers (MDIs) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019